Bioneer – Korea
Bioneer Corp., founded in 1992 as the first bio-venture in South Korea, is moving forward to a full-fledged molecular biotechnology company on the strength of the R&D infrastructure and intellectual properties.
Since beginning the home production of synthetic oligonucleotides and PCR enzymes with its proprietary technology for the first time in Korea, Bioneer has continuously built up expertise in molecular diagnostics and RNAi therapeutics. Bioneer is currently providing total solutions for molecular diagnostics in various disease areas through an integrated platform of reagents, instruments and analysis software. Bioneer’s SAMiRNA™ is a new paradigm of RNAi therapeutics in terms of being a much more efficient carrier compared to the conventional methods to deliver siRNA to the inside of a target cell.
Bioneer has vertically integrated genomic technology-based businesses, which provides competitive advantages in the market such as price competitiveness, product development efficiency and a high level of control. Today, Bioneer is operating businesses in the following three domains: Research-use products in genomics, biotechnology, molecular biology, etc.; Molecular diagnostic reagents, instruments and software; New development based on RNAi.